Drug Trial Radar · NCT06787950
Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Feb 20, 2025
Primary completion
Mar 20, 2029
Study completion Sep 20, 2029
Sponsor
- Lead sponsor
- Jiangsu Yahong Meditech Co., Ltd aka AsierisIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/IIa, open-label, multi-center, dose-escalation, and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of ASN-3186 when given orally in subjects with advanced solid tumors
Conditions
- Advanced Solid Tumors
Interventions
ASN-3186Drug
ASN-3186 will be administered orally.
ASN-3186Drug
ASN-3186 will be administered orally.
ASN-3186Drug
ASN-3186 will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- phase 1( Dose Escalation Stage): Dose Limiting Toxicity (DLT)Time frame: During the first 26 Days
- phase 1( Dose Escalation Stage): Recommended phase 2 dose(RP2D)Time frame: 14 months
- phase 2a: ORRTime frame: 26 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.